retatrutide human trials A New Obesity Drug Delivered Surgery-Level Weight Loss in Clinical Retatrutide Significantly Reduces Visceral Fat

Understanding how GLP-1 functions can help reframe your journey

Beyond glycemic control, activating GLP-1R exerts anti-inflammatory and antifibrotic effects on diverse fibrotic diseases, such as renal fibrosis, cardiac fibrosis, liver fibrosis and BLM-induced pulmonary fibrosis [25, 26]

A case series published in late 2025 in SAGE Open Medical Case Reports by Tinsley (Texas Tech University) and Nadolsky (Vineyard Health) provides the first detailed published body composition trajectories from a virtual obesity medicine practice that emphasizes structured resistance training and protein targets alongside incretin therapy

According to Leigh ODonnell, from Kantar, at the recent Sweets & Snacks Expo, 46% of users report they intend to make better food choices and 43% said they are overeating less

Switch sides, performing two or three times per side

The high dose segment dominated the GLP-1 targeted peptide weight loss drugs market in 2024